摘要
目的:观察阿魏酸钠对人经皮冠状动脉成形术(PCI)后的再狭窄是否具有预防作用,并观察PCI前后内皮素1(ET-1)与一氧化氮(NO)水平的变化。方法:选择行冠脉内支架安置术的急性冠脉综合征病人60例,随机分为2组,治疗组PCI术后予阿魏酸钠治疗。分别测量2组PCI术前,术后即刻、12 h、1 d、3 d、7 d的ET-1及NO水平。术后3 d行冠脉CT检查,测定支架处管腔面积,6 mo后再次行冠脉CT检查,测定支架处最窄处面积,分别计算2组6 mo后的管腔丢失率,并进行比较。结果: 2组术后即刻及12 h的ET-1水平较术前明显增高,2组对比,各个时段的ET-1水平均无明显差异(P> 0．05);NO水平在术前2组无明显差异,在治疗组术后即刻NO水平为(1．7±s 0．6)ng·L-1,对照组为(1．7±0．5)ng·L-1,无明显差异(P>0．05),但术后12 h、1 d、3 d、7 d的NO水平,治疗组明显高于对照组(P<0．01);6 mo后PCI术支架处的管腔丢失率在治疗组与对照组分别为(0．39±0．28)％,(0．5±0．3)％,治疗组的管腔丢失率明显低于对照组(P<0．01)。结论:PCI术后应用阿魏酸钠,可能有在受体水平阻滞ET-1的作用,同时增加NO水平,从而抑制内膜的增生,为预防PCI术后再狭窄提供了一个新的治疗手段。
AIM ： To observe the effects of sodium ferulate, an endothelin receptor antagonist, on restenosis after percutaneous coronary intervention （PCI）. METHODS： Sixty patients after PCI were randomized into the treatment group and the control group. Patients in the treatment group were treated with sodium ferulate after PCI. Coronary lumina lose rates were measured 6 mo after PCI through coronary CT. ET-1 and NO levels were tested before PCI, and immediately, 12 h, 1 d, 3 d, 7 d after PCI. RESULTS： The coronary lumina lose rate of the treatment group was lower than that of the control group （（0.39 ± s 0.28） % vs （0.5 ± 0.3） %, P 〈 0.01 ）. There was no significant difference of ET-1 level between two group （P 〉 0.05 ）. NO levels of the treatment group were higher than those of the control group （P 〈 0.01） at 12 h, 1 d, 3 d, 7 d after PCI. CONCLUSION： Endothelin receptor antagonist sodium ferulate is a new method to prevent restenosis after PCI.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2007年第2期128-130,共3页
Chinese Journal of New Drugs and Clinical Remedies
关键词
阿魏酸钠
血管成形术
经腔
经冠状动脉
受体
内皮缩血管肽
再狭窄
sodium ferulate
angioplasty, transluminal, percutaneous coronary
receptors, endothelin
restenosis
